Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and reliability of pressure algometry for mechanical nociceptive threshold quantification in lambs in a field environment.

Frontiers in pain research (Lausanne, Switzerland)·2026
Same author

Development and Application of an LC-MS/MS Assay for Plasma Propofol Quantification in Major Noncardiac Surgical Patients to Evaluate Target-Controlled Infusion Algorithms.

Therapeutic drug monitoring·2026
Same author

Suicidal Ideation Effectiveness and Safety Outcomes from the Ketamine for Adult Depression Study (KADS).

Archives of suicide research : official journal of the International Academy for Suicide Research·2026
Same author

Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study - RETRACTION.

The British journal of psychiatry : the journal of mental science·2026
Same author

Pre-treatment gut microbiome and salivary metabolome signatures associate with chemotherapy-induced cognitive decline in women with breast cancer: A prospective pilot study.

Cancer letters·2026
Same author

Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review.

British journal of anaesthesia·2025

Related Experiment Video

Updated: Jul 16, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Pharmacogenetics of opioids.

Andrew A Somogyi1, Daniel T Barratt, Janet K Coller

  • 1Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, Australia. andrew.somogyi@adelaide.edu.au

Clinical Pharmacology and Therapeutics
|March 7, 2007
PubMed
Summary

Genetic factors significantly influence how individuals respond to opioid pain relievers, affecting both efficacy and side effects. Understanding pharmacogenomics is key to optimizing opioid therapy for diverse patient populations.

Related Experiment Videos

Last Updated: Jul 16, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Area of Science:

  • Pharmacogenomics
  • Pain Management
  • Drug Metabolism

Background:

  • Opioids are crucial for pain management but exhibit significant interpatient variability in response.
  • Genetic factors influencing opioid pharmacokinetics and pharmacodynamics contribute to this variability.
  • Despite historical efforts, developing opioids with improved therapeutic margins has been challenging.

Purpose of the Study:

  • To explore the role of genetic factors in opioid variability.
  • To understand how genetic variations impact opioid efficacy and side effects.
  • To inform the application of pharmacogenomics in opioid therapy.

Main Methods:

  • Investigated genetic polymorphisms in metabolizing enzymes (e.g., CYP2D6).
  • Examined the influence of drug transporters (e.g., P-glycoprotein/ABCB1).
  • Assessed single-nucleotide polymorphisms in the mu opioid receptor gene.

Main Results:

  • CYP2D6 genotype affects codeine metabolism and antinociception.
  • ABCB1 genotypes show inconsistent effects on opioid response.
  • Mu opioid receptor gene polymorphisms correlate with morphine dosage but not methadone.

Conclusions:

  • Pharmacogenomic insights are essential for understanding opioid variability.
  • Further research into gene-drug interactions will improve opioid treatment strategies.
  • Personalized medicine approaches can enhance opioid therapy efficacy and safety.